The ‘PROFILE’ Innovative Trainning Network (European Industrial Doctorates programme) aims at stratifying acquired thrombotic thrombocytopenic purpura (TTP) patients by understanding disease pathology, using new types of biomarkers and predicting their risk for relapse.
The outcome of this project will be crucial for treatment adjustment in these patients and development of personalized medicine in the future. To stratify acquired TTP patients (or any other patients with an autoimmune disorder), a unique research approach and specialized translational training programme is needed.
The following objectives will be executed to achieve this innovative European Industrial Doctorates programme:
• Objective 1:
To decipher the pathophysiology of acquired TTP at the molecular level
• Objective 2:
To establish immunoprofiling as a new type of biomarker for the stratification of patients
• Objective 3:
To link biomarkers with disease prognosis
• Objective 4:
To develop novel treatment strategies and test them in preclinical animal models
• Objective 5:
To provide a unique translational training programme with important links to clinic and industry
• Objective 6:
Outreach, dissemination and exploitation
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 675746